Use at least 8 characters, an uppercase and a lowercase letter, and a number or symbol.
Please ensure your password has at least 8 characters, an uppercase and a lowercase letter, and a number or symbol.
By clicking Create Account and Subscribe you agree to us creating an account for you and subscribing you to our newsletter in accordance with our Privacy Policy and Legal Notice.
Emails, which may be sent daily or less frequently, may include marketing elements. We will not share your email address with any third parties. You can unsubscribe whenever you want.
By clicking Sign in and Subscribe you agree to us subscribing you to our newsletter in accordance with our Privacy Policy and Legal Notice.
(0)
-
Diffuse large B-cell lymphoma (DLBCL) is the most common aggressive form of Non-Hodgkin s Lymphoma (NHL), representing 30-40% of cases. Nearly half of DLBCL patients are not cured by first-line treatment, leaving a large number of patients at risk of worsening disease
1
-
Naratuximab emtansine, the most advanced CD37 targeting antibody drug conjugate (ADC) in clinical development for DLBCL, showed promising safety and efficacy results in combination with rituximab for the treatment of R/R DLBCL and other B-cell malignancies
-
Phase II data presented by Dr. Moshe Yair Levy at the 2021 European Hematology Association (EHA) conference as a late breaking abstract (LB1903) demonstrated that the naratuximab emtansine/rituximab combination could represent a new treatment approach, particularly for heavily pre-treated
GLOW study presented as a late-breaking abstract at the European Hematology Association (EHA) Virtual CongressBEERSE, Belgium (BUSINESS WIRE) The Janssen Pharmaceutical Companies of Johnson & Johnson today announced primary results from the pivotal Phase 3 GLOW study (NCT03462719) evaluating fixed-duration IMBRUVI.
/PRNewswire/ The PEGASUS phase-3 study previously demonstrated that pegcetacoplan, a drug controlling intra- and extravascular hemolysis, was superior to.
GLOW study presented as a late-breaking abstract at the European Hematology Association (EHA) Virtual Congress The Janssen Pharmaceutical Companies of Johnson Johnson today announced primary results